Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review

(2017) Robert Brody et al.   LUNG CANCER

Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity

(2017) Charny Park et al.   OncoImmunology

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications

(2016) Ruri Saito et al.   MODERN PATHOLOGY

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

(2016) Sarah Derks et al.   Oncotarget

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

(2015) Razvan Cristescu et al.   NATURE MEDICINE

Immune modulation for cancer therapy

(2014) J Naidoo et al.   BRITISH JOURNAL OF CANCER

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE